anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Occult liver disease refers to the presence of unrecognized chronic liver disease and cirrhosis. Liver disease is currently the eleventh cause of death globally, representing 4% of all deaths in the world. Alcohol consumption is the leading cause of cirrhosis globally, accounting for approximately 60% of cases. The estimated global prevalence of non-alcoholic fatty liver disease (NAFLD) is 32.4% and has been steadily increasing over the last years. Viral hepatitis B and C accounted for 1.3 million deaths in 2020. Several studies in populations at high risk of chronic liver disease (elevated liver enzymes, type 2 diabetes, excessive alcohol consumption) have found an elevated prevalence of occult liver disease. Attempts should be made to assess the prevalence of occult liver disease in Latin America, a region with one of the highest rates of metabolic diseases and excessive alcohol consumption. Screening for NAFLD in high-risk subjects and screening for excessive drinking and alcohol use disorders at every level of medical care is relevant. Efforts should also focus on the early treatment of occult liver disease to try to reduce liver disease burden and, in the case of occult viral hepatitis infection, prevent further spreading.
A method for preparing the peritoneal catgut from the serous coat of the cattle comprises the washing of the tissues with formalin. The visceral peritoneum separated from the cecum of the cattle is washed in tap water, soaked in 3 % solution of formaldehyde for 1-5 days, washed again in tap water for 10-12 min, and stretched on the smooth piece of glass previously degreased with ethanol and wiped with the dry paper. The specimen is stretched until complete removal of the folds. The stretched material is cut into the strips 0.2- wide. The strips are twisted into the threads and attached onto the frames for drying in the stretched position for 10-15 min. The dry catgut is immersed into 3 % solution of formaldehyde for 2-3 days, and then transferred into 75 % ethanol for 20-24 hours to remove the formaldehyde residues changing ethanol solution twice. Finally, the catgut is sterilized by irradiation or stored in 75 % ethanol.
The invention discloses an EGFR (epidermal growth factor receptor) inhibitor for targeted therapy of cancers, and a preparation method and application thereof. The structural formula of the EGFR inhibitor is disclosed as Formula I, wherein R is H, OH, NR', C1-C3 alkyl, C1-C3 alkenyl, aryl or heterocycle, and R' is C1-C3 alkyl. The EGFR inhibitor can be used for preventing and/or treating cancers, such as human skin squamous carcinoma or lung cancer. Compared with the existing inhibitors (such as AZD9291, afatinib and the like), the EGFR inhibitor disclosed by the invention has novel chemical structure. The EGFR inhibitor can selectively inhibit cell lines of EGFR double mutants (EGFRT790M/L858R), and has lower inhibition activities for EGFR wild type cells. Therefore, the EGFR inhibitor disclosed by the invention can be used for treating the patient with lung cancer with EGFRT790M/L858R mutants, and has lower side effect (caused by the inhibition of the wild type EGFR, such as afatinib).
This is an open-label (patients will know if they are receiving treatment and the identity of the treatment) study that will compare renal threshold of glucose (RTG) values obtained by 2 different methods: an established method (ie, the stepwise hyperglycemic clamp method) and a new method (the mixed meal tolerance test \[MMTT\] method). The RTG is defined as the lowest plasma glucose concentration at which appreciable amounts of glucose appear in the urine. Each method for determining the RTG value will be performed in untreated patients with type 2 diabetes mellitus (T2DM) and in patients with T2DM who are treated with canagliflozin 100 mg once daily for 8 days. Canagliflozin (a Sodium-Glucose Cotransporter 2 inhibitor) is currently under development to lower blood sugar levels in patients with T2DM. Patients will not take study drug (canagliflozin 100 mg overencapsulated tablets) in Part 1 of the study. In Part 2 of the study, patients will take study drug once daily on Study Days 1 through 8.
The invention discloses a medicine capable of promoting and improving sleep quality, which is characterized by mainly comprising the following raw materials: glossy ganoderma, tuckahoe, hericium erinaceus and gastrodia elata in the following proportion: 20-50%: 5-20%: 10-30%: 20-40%. The production method comprises selecting the above main raw materials, pulverizing the raw materials by ultramicro technology or extracting powder of polysaccharide crystal with hot water, mixing the corresponding fungus powder or extracted polysaccharide crystal powder raw materials at a certain ratio, homogenizing, sterilizing, and packaging. The medicine is prepared from four medicines according to a specific proportion, and is convenient to use. Has obvious effects of promoting sleep and solving the problem of insomnia and has wide adaptability. Has definite curative effect on secondary insomnia caused by chronic diseases such as tumors, hypertension, diabetes, nephropathy, heart disease and the like. The drug does not have dependence and addiction to the drug, and the drug resistance is not generated. The administration is safe and reliable.
The intervention group was supplemented with three sachets of MMS each week for every other day for a period of 12 months. Each sachet containing 1 g consisting of ten vitamins and five minerals. It was to be sprinkled over a cooked meal or dissolved in a drink for the child. Written instruction for using and storing the MMS in simple language with visuals was given prior to the supplementation. The intervention group also received health and nutrition advice at 3, 6 and 9 months after supplementation begins.
The invention provides lactobacillus plantarum ZJUIDS19, and preparation and application thereof. The classification of this strain was named: lactobacillus plantarum (Lactobacillus plantarum), accession number: CGMCC No.28018. The 16S rDNA complete sequence of the lactobacillus plantarum ZJUIDS19 is shown as SEQ ID No. 1. The invention is based on probiotics separated from inner Mongolian acid dairy products, and plant lactobacillus with antibacterial and antioxidant effects is selected from the probiotics, and its metayuan is extracted and compounded with modified lactalbumin to form a novel hydrogel material. The material has good antibacterial property, strong antioxidant capacity and biocompatibility, and can play a role in promoting wound healing as a wound dressing.
The invention relates to a novel Xuanmaiganju composition (composition consisting of radix scrophulariae, radix ophiopogonis, liquorice root and radix platycodonis) and a preparation method of the composition. The composition is mainly prepared from 10 parts of the radix scrophulariae, 10 parts of the radix ophiopogonis, 10 parts of the liquorice root and 10 parts of the radix platycodonis; and the preparation method comprises such steps as extracting four raw materials, namely the radix scrophulariae, the radix ophiopogonis, the liquorice root and the radix platycodonis, conducting alcohol precipitation, refining extracts by virtue of a macroporous resin column and the like. Modern pharmacological researches show that both the radix scrophulariae and the radix ophiopogonis have a bacteriostatic effect and have an obvious effect on inhibiting diplococcus pneumoniae, streptococcus hemolyticus, bacillus influenzae and the like. The liquorice root has functions of resisting inflammation and resisting allergy. The radix platycodonis is capable of promoting the secretion of respiratory mucosa and taking effects of eliminating phlegm and relieving sore throat. The composition provided by the invention adopts an effective composition group, and various components fully develop a synergistic effect, so that the curative effect of the medicine (the composition) is enhanced; and animal tests show that the composition provided by the invention has a good effect of preventing and treating throat diseases.
A functionalized active-nucleus complex sensor that selectively associates with one or more target species. The functionalized active-nucleus complex comprises an active-nucleus and a targeting carrier. The targeting carrier comprises a first binding region having at least a minimal transient binding of the active-nucleus to form the functionalized active-nucleus complex that produces a detectable signal when the functionalized active-nucleus complex associates with the target species and a second binding region that selectively associates with the target species. Included is a method for assaying and screening for one or a plurality of target species utilizing one or a plurality of functionalized active-nucleus complexes with at least two of the functionalized active-nucleus complexes having an attraction affinity to different corresponding target species. The method comprises the steps of functionalizing an active-nucleus, for each functionalized active-nucleus complex, by incorporating the active-nucleus into a macromolucular or molecular complex that is capable of binding one of the target species. Then bringing the macromolecular or molecular complexes into contact with the target species and detecting the occurrence of or change in a nuclear magnetic resonance signal from each of the active-nuclei in each of the functionalized active-nucleus complexes in order to either monitor the occurrence of binding between each of the functionalized active-nucleus complexes and the target species or monitor a subsequent change in the environment of the target species after the binding occurs.
Prader-Willi syndrome (PWS) is a genetic disease associated with sleep disorders whose etiology is partly central due to the inherent hypothalamic deficit. It is associated with low cognitive performance and worsening behavior with more impulsivity, tantrums, scratches and obsession for food. Deep propioceptive stimulation with a heavy blanket (HB) stimulates the parasympathetic system and improves the state of anxiety in persons with autism or other causes of intellectual disability and/or psychopathology. To date, there are no studies evaluating the effect of HB on sleep quality or brain activity in persons with PWS. The main objective is to study the effect of HB for 2 weeks compared to a placebo blanket on sleep quality and behavior in patients with SPW.

Methodology: Actigraphy, questionnaires, crossover study in 60 patients with PWS, with HB/placebo blankets (15 days each). Effect of HB on brain connectivity with functional magnetic resonance imaging in 30 patients and 30 controls. Expected results: PWS group will show worse sleep quality and behavior that will improve after using HB. Brain connectivity will be different with/without HB. These favorable changes will help to justify the use of this ecological treatment and its inclusion in the NHS clinical practice guidelines for improving the quality of life of these patients and their caregivers.
To determine the amount of opiate and pain medication administered in the week following surgery. Subjects will receive an identical pain control regimen. Participants will undergo TMS motor threshold assessment at the ETSU Innovation Lab prior to the planned surgery. At this appointment a baseline Beck Depression Inventory (BDI), Center for Epidemiological Studies 10-item Depression scale (CES-D) and visual analog scale (VAS) ratings of pain and mood will be obtained.VAS ratings will also be done each evening over the following week. One day after surgery, the subject will return to the Innovation lab for TMS. A total of 22 subjects will be recruited for the study. At the return visit, 11 will receive 40 minutes of 10 Hz repetitive TMS at 120% of rMT (4-second stimulation trains with 26-second interstimulus intervals). The other 11 participants will receive sham treatment under identical settings. Participants, medical staff providing clinical care to patients and raters will not know whether participants receive real or sham TMS. Patients will keep a log of pain medications used over the following week in addition to the VAS ratings. Follow-up will occur one week after the TMS therapy. The subject will turn in logs and repeat BDI and CES-D scales.
Following ethics approval by the ULSS 9, adults with THA (at 7 days after surgery), aged between 45 and 85 years old will be recruited for the study by the office worker of the rehabilitation hospital. Patients will be informed about the aim of the study and will sign the informed consent. Patients that decided to participate in the study will be randomized into two rehabilitation groups: experimental group and control group. Patients will be evaluated for reaching the baseline data from a physiotherapist blind to the aim of the study. Both groups (experimental and control) will receive the same clinical indications during hospitalization. Both groups will perform the same daily warm-up exercises supervised by physiotherapists external to the study investigation and will receive the same conventional-exercises program. In addition to this, each group will perform a second rehabilitation session with the virtual reality, using the Virtual Reality Rehabilitation System (VRRS), but in the control group, the sensors of VRRS will be not connected. The primary outcome will be the Timed Up and Go (TUG), the test used to assess mobility, balance, and walking.
The invention provides a recombinant or synthetic or engineered or non-naturally occurring poxvirus that contains and expresses DNA encoding a heterologous or exogenous antigen, epitope or immunogen and Flagellin or an operable binding portion thereof. The poxvirus can contain or be engineered to contain and express vaccinia host range gene K1L. The poxvirus can be attenuated as to mammals, e.g., NYVAC, NYVAC.1, NYVAC.2, avipox, canarypox, fowlpox, ALVAC, TROVAC, MVA, or MVA-BN. The invention also provides methods for inducing an immunological response involving the poxvirus, and compositions containing the poxvirus. The antigen, epitope or immunogen that the poxvirus expresses can be at least one  Plasmodium  antigen. The  Plasmodium  antigen(s), epitope(s) or immunogen(s) can be SERA, ABRA, Pfhsp70, AMA-1, Pfs25, Pfs16, CSP, PfSSP2, LSA-1 repeatless, MSA-1, AMA-1 or combination(s) thereof. Advantageously the poxvirus contains DNA coding for and expresses  Plasmodium  antigen(s) CSP, PfSSP2, LSA-1-repeatless, MSA-1, SERA, AMA-1 and Pfs25. Also, advantageously, the poxvirus is a NYVAC poxvirus. The invention thus also provides an anti-malarial immunogenic or immunological compositions comprising the poxvirus, and methods for inducing an immunogenic or immunological response against malaria or  Plasmodium  in a mammal comprising administering to the mammal the poxvirus or an immunological or immunogenic composition containing the poxvirus. The mammal can be a human.
The present invention describes methods of screening for or selecting a catalytic antibody effective to cleave a target peptide. In particular, in the selection method of the present invention a phage gene is selected that encodes a gene product necessary for the production of a phage. The phage, carrying the modified gene is introduced into a host. Also, a library of rearranged immunoglobulin genes in a cloning vector is introduced into host cells. The host cells are grown under conditions in which the immunoglobulin genes are expressed in the host cells. The presence of antibodies capable of cleaving the target peptide is identified on the basis of production of phage.
Rufinamide is a triazole derivative structurally unrelated to currently marketed antiepileptic drugs (AEDs). Rufinamide has the chemical name 1-[(2,6-difluorophenyl)methyl]-1H -1,2,3-triazole-4 carboxamide. It has an empirical formula of C10H8F2N4O and a molecular weight of 238.194. The drug substance is a white to off white color powder, crystalline, odorless and slightly bitter tasting neutral powder. Rufinamide is slightly soluble in dimethylsulfoxide, tetrahydrofuran and in methanol, very slightly soluble in alcohol and in acetonitrile, practically insoluble in water.

Rufinamide tablet USP is available for oral administration in film-coated tablets, scored on both sides, containing 100 mg, 200 mg and 400 mg of rufinamide. Inactive ingredients are colloidal silicon dioxide, corn starch, croscarmellose sodium, hypromellose, iron oxide red, lactose monohydrate, magnesium stearate, polyethylene glycol, polyvinyl alcohol, sodium lauryl sulphate, talc, titanium dioxide.

USP Dissolution Test 2 is used.
This invention provides use of a composition for the manufacture of a medicament for modifying a cellular response in a mammal. The composition to be used an effective amount of biodegradable nanoparticles for administration to a mammal, each of said nanoparticles comprising an active agent, a biodegradable polymer, and a bone targeting agent administering to a mammal an effective amount of a composition comprising a compound absorbed in a biodegradable nanoparticle which is attached to a bone targeting agent. The invention also provides the use of said composition for the manufacture of a medicament for modifying a cellular response in a mammalian cell comprising contacting the mammalian cell with biodegradable nanoparticles. The invention further provides the use of said composition for the manufacture of a medicament for delivering an exogenous substance to a mammal. In addition a composition is disclosed comprising the exogenous substance absorbed into a biodegradable nanoparticle, wherein the biodegradable nanoparticle is covalently attached to a bone targeting agent, and use thereof for the manufacture of a medicament for administration to a mammal. The invention also provides a composition and a process for preparating the composition comprising a biologically active or therapeutic agent of compound, a biodegradable nanoparticle, and a bone targeting agent.
Patients suffering from chronic plaque psoriasis, treated with adalimumab (40mg) subcutaneously every other week after an initial dose of 80 mg. Treatment duration of at least 24 weeks.
A protocol of neck motor control protocol will be adopted in our study. The exercises will be administered during six weeks, twice a week. One session will run in the outpatient clinic and the other will be home based. Half of the sessions will be comprised of orofacial strategies and the other half neck motor control exercises. Each exercise and technique will be administered 10 times for 10 seconds.
Cold-sensitive digital vasospasm has been observed in some acromegalic patients treated with Parlodel. The response, should it occur, can be reversed by reducing the dose of Parlodel and may be prevented by keeping the fingers warm. Cases of severe gastrointestinal bleeding from peptic ulcers have been reported, some fatal. Although there is no evidence that Parlodel increases the incidence of peptic ulcers in acromegalic patients, symptoms suggestive of peptic ulcer should be investigated thoroughly and treated appropriately. Patients with a history of peptic ulcer or gastrointestinal bleeding should be observed carefully during treatment with Parlodel.

Possible tumor expansion while receiving Parlodel therapy has been reported in a few patients. Since the natural history of growth hormone-secreting tumors is unknown, all patients should be carefully monitored and, if evidence of tumor expansion develops, discontinuation of treatment and alternative procedures considered.
Patients complete questionnaires over 15 minutes and undergo pain assessments prior to surgery and at 3, 6 and 12 months after surgery. Patients also undergo blood sample collection before surgery and optionally at 3, 6 and 12 months after surgery.
Participants may use other health services (GP, other interventions) as usual through the data Collection period (6 months). Afther this period, they will have the opportunity to join an ICDP-Group if they still want.
Spinal cord injury (SCI) is a serious, prolonged, and irreversible injury with few therapeutic options. Albiflorin (AF) possesses powerful pharmacodynamic properties and exerts protective effects against neuroinflammation. However, no research has examined the neuroprotective effect of AF following SCI. Rats were received laminectomy to establish SCI animal model and treated with AF (20 mg/kg and 40 mg/kg). Behavioral experiments were conducted to assess the impacts of AF on motor function after SCI in rats. Hematoxylin-eosin (HE) staining, Nissl staining, and Prussian Blue staining were performed to observe histological changes, neuronal damage, and iron deposition, respectively. Transmission electron microscope was adopted to observe the ultrastructure of spinal cord tissues. Immunofluorescence assay was performed to examine neurons and microglia. ELISA assay was used to examine the production of cytokines. Western blot assay was used to detect the expression level of ferroptosis-related proteins. Microglia BV-2 cells were induced by LPS to mimic the neuroinflammatory condition. Cell viability was assessed by CCK-8 assay, and lipid peroxidase level was measured by C11 BODIPY 581/591 staining. Molecular docking technology was utilized to confirm the relationship between AF and LSD1. AF improved the motor functional recovery after SCI in rats. Meanwhile, AF attenuated neuron apoptosis and microglia activation, reduced the production of pro-inflammatory cytokines and iron accumulation, and inhibited spinal cord ferroptosis following SCI in rats. LSD1 was verified to be a target protein of AF, and AF could concentration-dependently downregulate LSD1 expression in injured spinal cords in vivo and LPS-induced BV-2 cells in vitro. In addition, AF not only inhibited ferroptosis through reducing lipid peroxidase and iron levels and regulating ferroptosis-related proteins, but also inhibited microglial activation and reduced pro-inflammatory cytokines production in LPS-induced BV-2 cells; however, these changes were partly counteracted by LSD1 overexpression. AF could reduce microglial activation and ferroptosis, attenuate neuroinflammation, and improve functional recovery following SCI by downregulating LSD1, providing novel therapeutic strategies for the treatment of SCI.
There are disclosed vaccines which are effective for protecting a mammal against coronaviruses without inducing antibody dependent enhancement (ADE). In particular, there is disclosed a modified Feline Infectious Peritonitis virus (FIPV) S protein wherein at least one of the A1, A2 or D regions are antigenically-inactive. The S protein may have its signal peptide modified or deleted. Proteins for a FIPV vaccine may include the SM protein and/or the M protein. The protein sequence and corresponding nucleotide sequence of the FIPV SM protein is disclosed. The protein fragments may be attached to proteins such as BSA or KLH. The proteins may be formulated as a live vaccine e.g. by utilising recombinant carriers such as vaccinia, herpes, adeno, sinbis, corona viruses or bacterial carriers.
Currently, the guideline recommended re-perfusion such as intravenous thrombolysis and mechanical thrombectomy as the most effective treatment for acute ischemic stroke. However, the two methods are restricted by a strict time window, which greatly limits the number of the patients receiving treatment. The abundant studies have suggested that good collateral circulation can provide compensatory blood supply to save the ischemic penumbra and reduces the infarct volume, which improves the prognosis. How to improve collateral circulation in an efficient and safe way is a clinical challenge. Our recent experiment results of the animal and clinical experiments show that head-down position can significantly increase cerebral perfusion and improve neurological function. Clinically, head-down position is simple and easy to operate, and theoretically may increases brain perfusion and improve collateral circulation. A pilot randomized clinical trial is designed to investigate the effect of head-down position combined with routine rehabilitation in patients with ischemic stroke.